FDA Approves First Gene Therapy for Severe LAD-I

Last updated: 2026-04-06

The U.S. Food and Drug Administration has approved Kresladi (marnetegragene autotemcel), marking a historic milestone as the first gene therapy approved for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). The announcement, published via the FDA's official press release, signals not just a breakthrough for patients with this rare and life-threatening condition, but a broader shift in how regulators are approaching advanced therapy medicinal products (ATMPs) and gene therapy submissions.

For biotech sponsors, contract development and manufacturing organizations (CDMOs), and quality teams navigating the FDA's evolving framework for cell and gene therapies (CGTs), this approval is a case study worth studying closely.

What Is Leukocyte Adhesion Deficiency Type I (LAD-I)?

LAD-I is a rare, inherited primary immunodeficiency caused by mutations in the ITGB2 gene, which encodes the CD18 protein — a critical component of leukocyte integrins. Without functional CD18, white blood cells cannot effectively migrate from the bloodstream to sites of infection, leaving patients virtually defenseless against bacterial and fungal pathogens.

Severe LAD-I is life-threatening: Without definitive treatment such as hematopoietic stem cell transplantation (HSCT), the mortality rate in children with the severe form exceeds 60% by age two. Globally, LAD-I affects an estimated 1 in 100,000 to 1 in 1,000,000 live births, making it an ultra-rare disease even within the rare disease landscape.

Until now, allogeneic HSCT was the only curative option — but donor availability, graft-versus-host disease (GvHD), and conditioning-related toxicity remained significant barriers, particularly for pediatric patients who lack matched sibling donors.

Kresladi: What the Approval Covers

Kresladi (marnetegragene autotemcel) is an autologous, ex vivo lentiviral vector-based gene therapy. The treatment works by:

1. Collecting the patient's own hematopoietic stem and progenitor cells (HSPCs)
2. Transducing those cells with a lentiviral vector carrying a functional copy of the ITGB2 gene
3. Reinfusing the corrected cells after myeloablative conditioning

Because the therapy uses the patient's own cells, it eliminates the risk of donor-derived GvHD — one of the most serious complications associated with allogeneic HSCT.

This approval represents a Regenerative Medicine Advanced Therapy (RMAT) designation pathway success, demonstrating how FDA's expedited programs can compress development timelines for life-threatening pediatric conditions without compromising evidentiary standards.

Regulatory Pathway: How Kresladi Got Approved

Understanding how this therapy reached approval is as important as understanding what was approved. The regulatory journey for Kresladi illustrates several key mechanisms that sponsors developing CGTs should understand and leverage:

Breakthrough Therapy and RMAT Designations

The FDA's Breakthrough Therapy Designation (BTD) and RMAT Designation (established under the 21st Century Cures Act) are designed specifically to accelerate development of therapies addressing serious or life-threatening conditions. RMAT designation, in particular, allows for early and frequent interactions with FDA, rolling review, and priority review — all of which were critical for a therapy targeting an ultra-rare pediatric disease with high unmet medical need.

RMAT designation has been granted to over 60 gene and cell therapy programs since its creation in 2017, according to FDA CBER data, but very few have crossed the finish line to full approval. Kresladi's success is therefore instructive.

Accelerated Approval Considerations

For rare diseases with high unmet medical need and small patient populations, the FDA may grant approval based on surrogate or intermediate clinical endpoints reasonably likely to predict clinical benefit. Sponsors pursuing similar rare disease gene therapy programs should work closely with FDA early — through Type B and Type C meetings — to align on primary endpoints, follow-up duration, and post-marketing commitments.

CMC Complexity: The Manufacturing Challenge

Perhaps the single largest regulatory challenge for autologous gene therapies is Chemistry, Manufacturing, and Controls (CMC). Every Kresladi dose is, by definition, a unique product — manufactured from a single patient's cells, processed, tested, released, and administered, often under time-critical conditions.

The FDA's expectations for autologous CGT manufacturing are codified across multiple guidance documents, including: - Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) (January 2020) - Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-Up (November 2020) - Long Term Follow-Up After Administration of Human Gene Therapy Products (January 2020)

Compliance teams need to account for patient-specific lot release, lentiviral vector characterization, vector copy number (VCN) controls, insertional oncogenesis risk mitigation, and robust chain-of-identity (COI) systems. These are not theoretical concerns — they are active inspection focus areas.

What This Approval Means for Biotech and CGT Sponsors

The Kresladi approval sends several strong signals to the broader biopharmaceutical industry. Here is my analysis as someone who has guided 200+ clients through regulatory submissions and audits:

1. The FDA Is Committed to Rare Disease CGT Pathways

The approval of Kresladi — for a disease affecting a vanishingly small patient population — confirms that FDA's CBER is willing to work within the constraints of small clinical datasets when the unmet medical need is severe and the mechanistic rationale is strong. This is a signal to sponsors with rare disease programs: don't self-reject. Early engagement with FDA, through pre-IND meetings and RMAT designation requests, can unlock pathways that sponsors may not believe are accessible to them.

2. Long-Term Follow-Up (LTFU) Is Non-Negotiable

One of the most operationally intensive obligations that comes with gene therapy approval is the FDA's requirement for long-term follow-up — typically 15 years post-administration for integrating vectors like lentiviral vectors. Kresladi's approval will carry these obligations, and so will yours. Organizations need to build LTFU infrastructure — patient registries, standardized data collection instruments, and site monitoring plans — into their development programs from the outset, not as an afterthought at BLA submission.

3. Post-Market Commitments Are Real Commitments

Accelerated and standard approvals of CGTs routinely come with post-market study requirements. FDA has become increasingly assertive about enforcing these commitments. Sponsors who treat post-marketing studies as formalities do so at significant risk — to their product, their license, and their credibility with the agency.

4. Manufacturing Readiness Is a Regulatory Issue

In my experience working with CGT developers, the most common gap I identify during pre-inspection readiness reviews is the disconnect between clinical manufacturing and commercial manufacturing expectations. What works at a Phase I scale under investigational exemptions often does not meet 21 CFR Part 211 or Part 610 commercial expectations without significant process validation work, comparability studies, and facility upgrades.

The time to start commercial manufacturing planning is during Phase II, not after BLA submission.

Comparative Overview: Gene Therapy vs. Allogeneic HSCT for Severe LAD-I

Table 1: Comparative considerations for severe LAD-I treatment modalities

Compliance Implications: What Quality and Regulatory Teams Should Do Now

Whether you are developing a gene therapy, manufacturing lentiviral vectors, or providing CDMO services to CGT developers, the Kresladi approval creates both a benchmark and a compliance checklist. Here is what I recommend:

Audit Your IND/BLA Readiness Against Current CBER Guidance

CBER has issued a substantial body of guidance for CGTs over the past five years. Many sponsors are still operating against outdated assumptions. Conduct a gap assessment of your current regulatory package against the most current FDA guidances — particularly on potency assays (a historically weak area for autologous CGTs), process validation, and elemental impurities.

Revisit Your Replication-Competent Lentivirus (RCL) Testing Strategy

For lentiviral vector-based products like Kresladi, FDA expects comprehensive RCL testing at the vector lot level, at the drug product level, and during patient follow-up. Many sponsors underestimate the sensitivity and specificity requirements for validated RCL assays. If your current assay strategy was designed to a pre-2020 standard, it likely needs updating.

Establish or Validate Your Chain-of-Identity (COI) System

For autologous products, COI errors are not quality events — they are patient safety catastrophes. FDA inspectors scrutinize COI systems closely, including barcode systems, dual-operator verification procedures, and electronic batch record integrations. This is an area where investment in robust systems early pays significant dividends at pre-approval inspections (PAIs).

Engage with FDA Early and Often

I cannot overstate the value of pre-IND meetings, Type B meetings, and RMAT interactions for CGT programs. The Kresladi approval was not achieved by a sponsor who submitted a BLA and hoped for the best. It reflects years of collaborative dialogue with CBER. If your program lacks a structured FDA engagement strategy, that is a gap that Certify Consulting can help close.

The Broader Signal: Gene Therapy Is Becoming a Regulated Commercial Reality

When the FDA approved the first gene therapy for an inherited disease — Luxturna (voretigene neparvovec) in 2017 — it was viewed as an outlier. Today, with Kresladi and a growing pipeline of approved CGTs, gene therapy is transitioning from experimental medicine to regulated commercial practice.

As of early 2025, FDA's CBER has received over 4,000 IND applications for gene therapy products, with the active pipeline representing the largest concentrated wave of novel biologics in the agency's history. For compliance professionals, this means that the regulatory frameworks, inspection programs, and enforcement actions that govern conventional biologics are being actively adapted and applied to CGTs — often faster than the industry anticipates.

The approval of Kresladi is a data point in that trajectory. But it is also a reminder that the regulatory pathway for gene therapy rewards sponsors who invest in quality systems, manufacturing controls, and proactive FDA engagement from Day One of development.

Expert Commentary: What Sets Successful CGT Programs Apart

After more than eight years and over 200 client engagements — with a 100% first-time audit pass rate — I have observed a consistent pattern in the gene therapy programs that succeed versus those that stall.

The programs that succeed share three characteristics:

1. Quality is built in, not bolted on. Quality by design (QbD) principles are applied to process development, not just to final product testing. Critical quality attributes (CQAs) and critical process parameters (CPPs) are identified early and controlled rigorously.

2. Regulatory strategy is integrated with development strategy. The regulatory affairs function is not downstream of development — it is embedded in decision-making from preclinical planning through commercial launch.

3. Leadership understands that compliance is a competitive advantage. In a space where a single clinical hold or Warning Letter can set a program back by two to three years, organizations that invest in compliance infrastructure consistently outperform those that treat it as an overhead cost.

Kresladi's approval is a celebration for patients with severe LAD-I and their families. It is also a case study in what is possible when science, manufacturing excellence, and regulatory strategy align.

How Certify Consulting Can Help

At Certify Consulting, we specialize in helping biotech sponsors, CDMOs, and medical product developers navigate FDA's complex regulatory landscape — including for cell and gene therapy programs. Our services include:

• Pre-IND and BLA regulatory strategy development
• CMC gap assessments and process validation support
• Pre-inspection readiness reviews and mock FDA audits
• Quality Management System (QMS) design and implementation
• Long-term follow-up (LTFU) program design

Whether you are entering the CGT space for the first time or preparing for a pre-approval inspection, our team brings the credentials, experience, and track record to help you get it right — the first time.

Learn more about our regulatory consulting services for biologics and advanced therapies or contact us directly to discuss your program.

Source: U.S. Food and Drug Administration. "FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I." FDA Press Announcements. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i

Last updated: 2026-04-06